Original Article
The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia
N Engl J Med 2004; 351:145-153July 8, 2004
- Abstract
Background
Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells. Dexrazoxane, a free-radical scavenger, may protect the heart from doxorubicin-associated damage.
Methods
To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes, we randomly assigned 101 children with ALL to receive doxorubicin alone (30 mg per square meter of body-surface area every three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediately by doxorubicin. Serial measurements of serum cardiac troponin T were obtained in 76 of 101 patients in the doxorubicin group and 82 of 105 patients in the group given dexrazoxane and doxorubicin. A total of 2377 serum samples (mean, 15.1 samples per patient) were obtained before, during, and after treatment with doxorubicin. Troponin T levels were evaluated in a blinded fashion to determine whether they were elevated (>0.01 ng per milliliter) — the primary end point — or extremely elevated (>0.025 ng per milliliter).
Results
Elevations of troponin T occurred in 35 percent of the patients (55 of 158). Patients treated with doxorubicin alone were more likely than those who received dexrazoxane and doxorubicin to have elevated troponin T levels (50 percent vs. 21 percent, P<0.001) and extremely elevated troponin T levels (32 percent vs. 10 percent, P<0.001). The median follow-up was 2.7 years. The rate of event-free survival at 2.5 years was 83 percent in both groups (P=0.87 by the log-rank test).
Conclusions
Dexrazoxane prevents or reduces cardiac injury, as reflected by elevations in troponin T, that is associated with the use of doxorubicin for childhood ALL without compromising the antileukemic efficacy of doxorubicin. Longer follow-up will be necessary to determine the influence of dexrazoxane on echocardiographic findings at four years and on event-free survival.
Media in This Article
Figure 1
Kaplan–Meier Plot of Event-free Survival after a Median Follow-up of 2.7 Years.Figure 2
Percentage of Patients with at Least One Elevated Cardiac Troponin T Level Overall, before Treatment with Doxorubicin, and during Treatment.Article Activity
- Article
The five-year survival rate among children who receive a diagnosis of cancer during the first 14 years of life is 77 percent.1 There are more than 250,000 survivors of childhood cancer in the United States, and an estimated 1 in 570 such young adults will be 20 to 34 years old by 2010.1 This success brings a new challenge: understanding and minimizing the late effects of therapies for cancer administered to children. More than 50 percent of long-term survivors of childhood cancer were treated with doxorubicin or another anthracycline.2 Many of those who were treated with doxorubicin have long-term problems,3-11 such as impaired left ventricular contractility, late congestive heart failure, or high-grade ectopy, and an increased risk of sudden death and death from cardiac causes. One study estimated that the risk of death from cardiac causes was 8.2 times that of the normal population even 25 years after therapy.12 A second study found that the risk of death from cardiac causes increased by a factor of 5.8 and that of sudden death, presumably from cardiac causes, by a factor of 3.9.13 These sequelae were related, in part, to the use of doxorubicin, and the incidence has not decreased during more recent treatment eras.14
Doxorubicin is an effective therapy for acute lymphoblastic leukemia (ALL),15 the most common cancer in children. A doxorubicin-containing protocol for children with high-risk ALL has resulted in the highest five-year event-free survival rate: 81 percent.16 In long-term survivors of childhood ALL, doxorubicin-associated cardiotoxic effects are pervasive, persistent, and often progressive.3-9
The serum level of cardiac troponin T is an accurate surrogate for acute myocardial injury in children,9,17-19 specifically that related to doxorubicin,20-23 and the maximal cardiac troponin T level during doxorubicin therapy is significantly correlated with the cumulative dose of doxorubicin24 and with subsequent structural abnormalities of the left ventricle seen on echocardiograms in these patients.17 A continuous 48-hour infusion of doxorubicin was not found to be more cardioprotective than bolus administration in patients with childhood ALL.25 Enalapril therapy delayed but did not prevent progressive, late cardiotoxic effects in long-term survivors of childhood cancer who had received doxorubicin.26
The only effective way to avoid late cardiotoxic effects appears to be to prevent cardiac injury during chemotherapy.27 A promising possibility involves treatment with dexrazoxane, a free-radical scavenger that is cardioprotective in adults receiving anthracycline therapy.27-32 Dexrazoxane may also be useful in children, although there is concern that this agent may protect tumor cells from chemotherapy.27,33-41 We conducted a multicenter, randomized, controlled trial to determine whether dexrazoxane therapy reduces myocardial injury, as measured by serum cardiac troponin T levels, in children with newly diagnosed ALL who are being treated with doxorubicin.
Methods
Patients
This study was part of the multiagent chemotherapy regimen in the Dana–Farber Cancer Institute childhood ALL consortium protocol 95-001. The study was approved by the institutional review board of each participating institution, and informed consent was obtained before treatment from all participants or their families or guardians. Between January 1996 and September 2000, all children in the consortium who were under 18 years of age and had newly diagnosed and previously untreated high-risk ALL (excluding known mature B-cell ALL) were invited to enroll in this study. Patients with standard-risk disease, as defined by an age between 1 and 10 years, a white-cell count of less than 50,000 cells per cubic millimeter at presentation, and the absence of T-cell markers, an anterior mediastinal mass, and central nervous system disease, were excluded. All other patients were classified as being at high risk, including infants and patients with T-cell disease.
Randomization
Randomization involved a permuted-block design and was carried out centrally at the Dana–Farber Cancer Institute's Quality Assurance Office for Clinical Trials before patients received doxorubicin or dexrazoxane. In addition to receiving multiagent chemotherapy and central nervous system radiation, patients with high-risk ALL received two doses of doxorubicin (30 mg per square meter of body-surface area per dose) during remission induction, followed by eight more doses (30 mg per square meter every three weeks) during induction therapy (cumulative dose, 300 mg per square meter). No doxorubicin was given after nine months of therapy. Patients at high risk were randomly assigned to receive doxorubicin alone or dexrazoxane (300 mg per square meter) immediately followed by doxorubicin. Local centers and patients were not blinded to the assignment with respect to dexrazoxane therapy, but central investigators performing troponin T measurements and echocardiographic evaluations and providing summary study results remained blinded throughout the study. An independent data-monitoring committee reviewed data on enrollment, adverse effects, and troponin T levels every six months and released the troponin T results when all patients had completed doxorubicin therapy.
Cardiac Troponin T
The protocol included the collection of serum at standardized times — at diagnosis (before doxorubicin therapy), daily after induction doses of doxorubicin, seven days after a dose of doxorubicin during induction therapy, and at the completion of therapy — for the measurement of cardiac troponin T. Serum collected at clinical sites was immediately frozen and stored at –70°C until it was assayed for cardiac troponin T at a central core laboratory with the use of the Elecsys Troponin T STAT Immunoassay (Roche Diagnostics), which has a sensitivity of 0.01 ng per milliliter.17 Hemolyzed samples were excluded. The members of the central laboratory for the measurement of cardiac troponin T remained unaware of the patients' treatment status. Serum cardiac troponin T results were entered directly into the central data base and were not reported to the various centers.
Echocardiograms
Echocardiograms were available for a subgroup of patients who underwent randomization, since cardiac troponin T was the primary marker of cardiac injury during therapy. Echocardiograms were required before the initiation of doxorubicin therapy and recommended at the end of induction therapy, after cumulative doses of 150 and 300 mg of doxorubicin per square meter had been received, and at the completion of all therapy. Echocardiography is also being performed at four years after diagnosis, and the resulting information will provide the primary measure of cardiac function. Patients with the most severely impaired cardiac function had the most echocardiograms, and thus, including all echocardiograms in the analysis could have biased the results. Therefore, we analyzed the latest echocardiogram obtained from each patient in each period: before, during, and after doxorubicin therapy. All echocardiograms were reevaluated by a single sonographer, who was unaware of the patients' clinical data.4 Each study consisted of two-dimensional echocardiography and Doppler evaluation.1,2,5 We measured fractional shortening, an index of left ventricular systolic performance influenced by heart rate, preload, afterload, and contractility, and the stress-velocity index, a load-independent index of contractility that incorporates preload and heart rate and varies with afterload.1,2,5 Diastolic function was not assessed.
Statistical Analysis
Fisher's exact test and the Kruskal–Wallis test were used to compare baseline characteristics and the frequency of elevated cardiac troponin T levels (defined as those above 0.01 ng per milliliter) — the primary end point of this analysis — and of extremely elevated levels (defined as those above 0.025 ng per milliliter) between treatment groups.42 Repeated-measures analysis of cardiac troponin T samples was used. Logistic regression was used to identify covariates associated with elevated cardiac troponin T levels.43 The time to event was either zero for patients with induction failure or those who died during induction or the time from complete remission to relapse, death during remission, or the last follow-up visit, whichever occurred first. Event-free survival was estimated according to the Kaplan–Meier method, with data on the time to event censored for patients who were in complete continuous remission at the time of data analysis.44
To adjust echocardiographic data for changes associated with growth, we calculated the z score (the number of standard deviations a measurement is above or below the predicted value) by dividing the difference between a child's observed cardiac outcome and the normal predicted value by the standard deviation of a distribution of normal values. We used data from 285 children evaluated at the same center and in the same manner as the study patients to calculate the normal predicted value according to a regression model.1,2,5 The z scores for left ventricular dimension were adjusted for body-surface area, and those for fractional shortening were adjusted for age. Echocardiographic data were analyzed with the use of t-tests and repeated-measures analysis. All reported P values are two-sided.
Results
Study Cohorts
A total of 219 children with high-risk ALL were enrolled, but 13 eligible patients did not undergo randomization (11 because of the parents' or patient's refusal and 2 because of logistical problems). The randomized cohort of 206 patients was used for the analysis of event-free survival and adverse effects. Nine patients (5 in the doxorubicin group and 4 in the group given dexrazoxane and doxorubicin) did not have a complete remission, and 39 others (20 and 19, respectively) did not have data on cardiac troponin T values because specimens were not available at the time of analysis. The percentage of patients without samples available varied according to the study center but was evenly divided according to treatment group. The remaining 158 patients formed the cohort used for the cardiac troponin T analyses. The randomized cohort and the cardiac troponin T cohort were similar with respect to age, sex, the cumulative dose of doxorubicin, and the absence of reported congestive heart failure or symptomatic arrhythmias. No patient who had undergone randomization refused to participate, failed to receive or discontinued dexrazoxane as assigned, or was excluded from the analysis.
The treatment groups did not differ significantly with respect to baseline characteristics (Table 1Table 1
Characteristics of the Patients.). There were no cases of congestive heart failure or other symptomatic cardiac disease. Transient cardiomyopathy developed 16 months after the completion of doxorubicin therapy in one patient treated with doxorubicin alone. Figure 1Figure 1Kaplan–Meier Plot of Event-free Survival after a Median Follow-up of 2.7 Years. shows the Kaplan–Meier estimates of event-free survival, with a median follow-up of 2.7 years; the event-free survival rates at 2.5 years were 83 percent in both groups (P=0.87).Cardiac Troponin T
A total of 2377 serial measurements of cardiac troponin T were obtained (mean, 15.1 samples per patient). As compared with the patients in the doxorubicin group, significantly fewer patients in the group given dexrazoxane and doxorubicin had any elevations in cardiac troponin T (21 percent vs. 50 percent, P<0.001), any extreme elevations in cardiac troponin T (10 percent vs. 32 percent, P<0.001), or multiple elevations in cardiac troponin T (12 percent vs. 37 percent, P<0.001) (Table 2Table 2
Frequency of Elevations in Serum Cardiac Troponin T.).Timing of Elevations in Cardiac Troponin T
Figure 2Figure 2
Percentage of Patients with at Least One Elevated Cardiac Troponin T Level Overall, before Treatment with Doxorubicin, and during Treatment. shows the percentage of patients in each group who had an elevated cardiac troponin T level at least once, overall, before treatment, and during doxorubicin therapy. Differences between the groups in the percentage of patients with at least one elevated cardiac troponin T level began to emerge between 61 and 120 days after the start of therapy, and these differences persisted throughout the rest of the treatment period, becoming significant during the interval between 121 and 180 days (P<0.001). Patients in the doxorubicin group also had a higher rate of elevation over time in comparison with those in the group given dexrazoxane and doxorubicin (P=0.003). Figure 3Figure 3
Percentage of Patients with at Least One Extremely Elevated Cardiac Troponin T Level Overall, before Treatment with Doxorubicin, and during Treatment. shows that the same pattern was evident for differences in the incidence of extremely elevated cardiac troponin T levels. Analyses including only the 86 patients with at least one measurement of cardiac troponin T during days 181 to 240 of doxorubicin therapy yielded results over time that were very similar to those shown in Figure 2 and Figure 3.Patients with Pretreatment Elevations in Cardiac Troponin T
Ten percent of the children in whom cardiac troponin T was measured before the initiation of doxorubicin therapy had an elevated cardiac troponin T level (12 of 119), indicating the presence of myocardial injury unrelated to the chemotherapy. As compared with patients who did not have an elevated cardiac troponin T level before doxorubicin treatment, those who did had a higher rate of elevated levels (73 percent vs. 27 percent, P=0.004) and of extremely elevated levels (58 percent vs. 17 percent, P=0.003) after doxorubicin treatment began. Children who had elevated levels before treatment had higher baseline white-cell counts (median, 300,300 vs. 27,200 cells per cubic millimeter; P<0.001) and a higher percentage of blasts (median, 89.0 percent vs. 57.5 percent; P=0.003). Differences between these two groups in the extent of T-cell disease or central nervous system disease, morphologic findings, sex, or age were not significant. When the children who had elevated cardiac troponin T levels before treatment were excluded from the analysis, treatment with dexrazoxane remained a significant cardioprotective factor (Table 2).
Prognostic Factors
We used a logistic-regression analysis to determine whether covariates other than treatment group were associated with elevated cardiac troponin T levels. Covariates were sex (male vs. female), race (white vs. nonwhite), age (<10 vs. ≥10 years), and the cumulative dose of doxorubicin (<300 vs. ≥300 mg per square meter). None of these covariates were significant (data not shown).
Echocardiographic Data
A total of 462 echocardiograms were obtained in eligible patients who underwent randomization, for whom cardiac troponin T data were available, and who had a complete remission (median, 2.5 echocardiograms per patient [2.0 per patient in the doxorubicin group and 3.0 per patient in the group given dexrazoxane and doxorubicin]). Echocardiograms obtained before doxorubicin therapy showed normal left ventricular fractional shortening (84 echocardiograms; mean z score, 0.19; P=0.51) and contractility (22 echocardiograms; mean z score, –0.02; P=0.96) but slight left ventricular dilatation, as reflected by the left ventricular dimension (79 echocardiograms; mean z score, 0.28; P=0.03). A total of 162 echocardiograms were obtained during doxorubicin therapy, and 164 were obtained a median of 198 days after the completion of therapy. After treatment, fractional shortening (91 echocardiograms; mean z score, –1.06; P<0.001) and contractility (29 echocardiograms; mean z score, –0.82; P=0.02) were depressed and the left ventricular dimension was normal (89 echocardiograms; mean z score, 0.01; P=0.92). There were no significant differences between the children who received doxorubicin alone and those who received dexrazoxane and doxorubicin with respect to the mean left ventricular dimension, fractional shortening, or contractility before, during, or after doxorubicin therapy. Fractional shortening was significantly depressed in both randomized groups during and after doxorubicin therapy.
Discussion
Dexrazoxane therapy was associated with a large and statistically significant reduction in the incidence of myocardial injury, as indicated by troponin T elevations, in doxorubicin-treated children with high-risk ALL. Dexrazoxane reduced the percentage of patients with any elevation in cardiac troponin T, multiple elevations, and extreme elevations. Because dexrazoxane reduces free-radical injury, our findings suggest that doxorubicin-associated myocardial injury in children may be related, at least in part, to oxidative damage. Doxorubicin forms a complex with iron that is thought to facilitate the formation of toxic oxygen radicals in tissues.45 The attenuating effect of dexrazoxane on doxorubicin-induced cardiotoxicity may be attributable to its intracellular conversion to its active metal ion-binding form (ADR-925), which either removes iron from the doxorubicin–iron complex or binds free iron, thus preventing the formation of oxygen radicals.46
Troponins are sensitive and specific markers of myocardial injury. In the absence of injury, troponin levels are usually below the limit of detection of current analytical methods. Low-level elevations have significant prognostic value in patients with unstable angina and myocardial infarction but without ST-segment elevation,47 since those with baseline cardiac troponin T levels between 0.01 and 0.05 ng per milliliter are at higher risk for death and myocardial infarction at one and six months than are patients with levels below 0.01 ng per milliliter.48 We have previously demonstrated that low-level elevations of cardiac troponin T induced by doxorubicin are associated with histologic evidence of myocardial injury and are clinically meaningful.21 Our current findings are similar to our finding that dexrazoxane-treated rats had less frequent elevations in cardiac troponin T and less severe cardiac injury on histologic analysis and were in better health than rats that did not receive dexrazoxane.41
The degree of cardiac injury identified after the first dose of doxorubicin treatment is related to the likelihood of subsequent echocardiographic abnormalities on the completion of therapy.17 Now, we have shown that the incidence of doxorubicin-associated elevations in cardiac troponin T increases substantially during doxorubicin therapy, persists throughout treatment, and is dramatically reduced by dexrazoxane therapy. Pretreatment with dexrazoxane reduces the late cardiotoxic effects of doxorubicin. Low-level elevations of cardiac troponin T are meaningful predictors of late cardiotoxic effects and may be used to guide preventive and therapeutic strategies to reduce these adverse effects. Children with higher percentages of leukemic blasts in the peripheral blood at baseline were more likely than those with lower values to have cardiac injury at diagnosis that was unrelated to doxorubicin.
We used cardiac troponin T instead of echocardiographic measurements as an indicator of myocardial injury because of the poor sensitivity and specificity of echocardiography in identifying subclinical abnormalities of left ventricular structure and function in children with cancer who are receiving doxorubicin.49,50 Our results suggest that echocardiographic measurements are not valid surrogates for subclinical myocardial injury in this setting. Other factors, such as abnormal heart rate, abnormal loading conditions, and the presence of cytokine-mediated myocardial depressants, may affect these echocardiographically derived measurements and result in values that may misrepresent the extent of subclinical doxorubicin-associated myocardial injury. These confounders of active myocardial injury are likely to be transient, a finding that may have implications with respect to the accuracy of echocardiographic monitoring for low-level myocardial injury during doxorubicin therapy.
Our findings demonstrate the efficacy of a cardioprotectant agent in children.9 Free-radical damage is a common mechanism of cardiac injury in children during the perinatal period, as well as in children with myocarditis, those with hypoxia and reoxygenation related to myocardial infarction or stroke,51 and those undergoing cardiopulmonary bypass or hemodialysis.9,17-19 Because children are still growing, minor myocardial injury has a greater chance of producing subsequent myocardial impairment in children than in adults.3,4,13
The optimal dose of dexrazoxane is unknown.9 Dexrazoxane has a short half-life, and repeated doses52 or continuous infusions53 may provide additional cardioprotection in patients with persistent elevations of cardiac troponin T. Further echocardiographic follow-up of this cohort is needed to identify any long-term cardioprotective effects of dexrazoxane.2-5 Continued monitoring of event-free survival in these patients will allow us to confirm that the cardioprotective effects of dexrazoxane do not reduce the antileukemic efficacy of doxorubicin.
Supported in part by grants from the National Institutes of Health (CA 68484, CA 79060, CA 55576, CA 06516, HL 59837, HR96041, HL 53392, and HL 72705), Pfizer, and Roche Diagnostics.
Dr. Lipshultz reports having received investigator-initiated research grant support from Pfizer, the manufacturer of dexrazoxane (Zinecard), and Roche Diagnostics, the manufacturer of the troponin T assay used in this study. Neither company had any active involvement in the study. Dr. Lipshultz reports having received an honorarium as a consultant for Chiron, which manufactures a product related to dexrazoxane (Cardioxane).
Source Information
From the Department of Pediatrics, University of Miami School of Medicine, Holtz Children's Hospital of the University of Miami/Jackson Memorial Medical Center and the Sylvester Comprehensive Cancer Center, Miami (S.E.L.); Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, N.Y. (S.E.L., B.L.A.); the Departments of Laboratory Medicine and Pathology, Children's Hospital, Boston (N.R.); the Departments of Pediatric Oncology (V.M.D., L.B.S., S.E.S.) and Biostatistical Science (D.E.L., S.R.L., R.D.G.), Dana–Farber Cancer Institute, Boston; the Division of Hematology/Oncology (L.B.S., S.E.S.) and the Department of Cardiology (S.D.C.), Children's Hospital, Boston; the Department of Pediatrics, Harvard Medical School, Boston (L.B.S., S.D.C., S.E.S.); the Department of Biometry and Epidemiology, Medical University of South Carolina, Charleston (S.R.L.); the Department of Pediatrics, McMaster University, Hamilton, Ont., Canada (R.D.B.); San Jorge Children's Hospital, Santurce, Puerto Rico (L.A.C.); Maine Children's Cancer Program, Barbara Bush Children's Hospital at Maine Medical Center, Portland (C.A.H.); St. Justine Hospital, Montreal (A.M.); Le Centre Hospitalier Universitaire de Québec, Quebec Canada (Y.S.); and the Department of Pediatrics, Ochsner Clinic Foundation and Tulane University School of Medicine, New Orleans (M.A.S.).
Address reprint requests to Dr. Lipshultz at the Department of Pediatrics (D820), University of Miami School of Medicine, P.O. Box 016820, Miami, FL 33101, or at slipshultz@med.miami.edu.
- References
References
1
US National Cancer Institute Workshop on Pediatric Oncology Late Effects of Childhood Cancer Networks. Background statistics on pediatric survivorship. Niagara-on-the-Lake, Canada, June 26, 2002.
2
Krischer JP ,Epstein S ,Cuthbertson DD ,Goorin AM ,Epstein ML ,Lipshultz SE . Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544-1552
Web of Science | Medline3
Lipshultz SE ,Colan SD ,Gelber RD ,Perez-Atayde AR ,Sallan SE ,Sanders SP . Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-815
Full Text | Web of Science | Medline4
Lipshultz SE ,Lipsitz SR ,Mone SM , et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-1743
Full Text | Web of Science | Medline5
Nysom K ,Holm K ,Lipsitz SR , et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:545-550
Web of Science | Medline6
Grenier MA ,Lipshultz SE . Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25:Suppl 10:72-85
Web of Science | Medline7
Giantris A ,Abdurrahman L ,Hinkle A ,Asselin B ,Lipshultz SE . Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998;27:53-68
CrossRef | Web of Science | Medline8
Nysom K ,Colan SD ,Lipshultz SE . Late cardiotoxicity following anthracycline therapy for childhood cancer. Prog Pediatr Cardiol 1998;8:121-138
CrossRef9
Lipshultz SE . Ventricular dysfunction clinical research in infants, children and adolescents. Prog Pediatr Cardiol 2000;12:1-28
CrossRef | Medline10
Kremer LC ,van Dallen EC ,Offringa M ,Ottenkamp J ,Voute PA . Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001;19:191-196
Web of Science | Medline11
Green DM ,Grigoriev YA ,Nan B , et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 2001;19:1926-1934
Web of Science | Medline12
Mertens AC ,Yasui Y ,Neglia JP , et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001;19:3163-3172
Web of Science | Medline13
Moller TR ,Garwicz S ,Barlow L , et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 2001;19:3173-3181
Web of Science | Medline14
Green DM ,Hyland A ,Chung CS ,Zevon MA ,Hall BC . Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. J Clin Oncol 1999;17:3207-3215
Web of Science | Medline15
Silverman LB ,Declerck L ,Gelber RD , et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000;14:2247-2256
CrossRef | Web of Science | Medline16
Silverman LB ,Gelber RD ,Dalton VK , et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-1218
CrossRef | Web of Science | Medline17
Lipshultz SE ,Rifai N ,Sallan SE , et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997;96:2641-2648
Web of Science | Medline18
Ottlinger ME ,Pearsall L ,Rifai N ,Lipshultz SE . New developments in the biochemical assessment of myocardial injury in children: troponins T and I as highly sensitive and specific markers of myocardial injury. Prog Pediatr Cardiol 1998;8:71-81
CrossRef19
Lipshultz SE ,Somers MJ ,Lipsitz SR ,Colan SD ,Jabs K ,Rifai N . Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. Pediatrics 2003;112:79-86
CrossRef | Web of Science | Medline20
Herman EH ,Lipshultz SE ,Rifai N , et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res 1998;58:195-197
Web of Science | Medline21
Herman EH ,Zhang J ,Lipshultz SE , et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999;17:2237-2243
Web of Science | Medline22
Herman EH, Ferrans VJ. The use of cardiac biomarkers for the detection of drug-induced myocardial damage. In: Adams JE III, Apple FS, Jaffe AS, et al., eds. Markers in cardiology: current and future clinical applications. Armonk, N.Y.: Futura Publishing, 2001:211-34.
23
Herman EH, Lipshultz SE, Ferrans VJ. The use of cardiac biomarkers to detect myocardial damage induced by chemotherapeutic agents. In: Wu AHB, ed. Cardiac markers. 2nd ed. Totowa, N.J.: Humana Press, 2003:87-109.
24
Lipshultz S ,Sallan S ,Dalton V , et al. Elevated serum cardiac troponin-T as a marker for active cardiac injury during therapy for childhood acute lymphoblastic leukemia (ALL). Prog Proc Am Soc Clin Oncol 1999;18:568a-568a abstract.25
Lipshultz SE ,Giantris AL ,Lipsitz SR , et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002;20:1677-1682
CrossRef | Web of Science | Medline26
Lipshultz SE ,Lipsitz SR ,Sallan SE , et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002;20:4517-4522
CrossRef | Web of Science | Medline27
Lipshultz SE . Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 1996;14:328-331
Web of Science | Medline28
Speyer JL ,Green MD ,Kramer E , et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745-752
Full Text | Web of Science | Medline29
Swain SM . Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 1998;25:Suppl 10:43-47
Web of Science | Medline30
Hellmann K . Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique. J Clin Oncol 2000;18:2004-2006
Web of Science | Medline31
Schluchter LM ,Hensley ML ,Meropol NJ . 2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20:2895-2903
CrossRef | Web of Science | Medline32
Seymour L ,Bramwell V ,Moran LA . Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. Cancer Prev Control 1999;3:145-159
Medline33
Wexler LH ,Andrich MP ,Venzon D , et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996;14:362-372
Web of Science | Medline34
Vats T ,Kamen B ,Krischer JP . Phase II trial of ICRF-187 in children with solid tumors and acute leukemia. Invest New Drugs 1991;9:333-337
CrossRef | Web of Science | Medline35
Holcenberg JS ,Tutsch KD ,Earhart RH , et al. Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep 1986;70:703-709
Medline36
Schiavetti A ,Castello MA ,Versacci P , et al. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Pediatr Hematol Oncol 1997;14:213-222
CrossRef | Web of Science | Medline37
Bu'Lock FA ,Gabriel HM ,Oakhill A ,Mott MG ,Martin RP . Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 1993;70:185-188
CrossRef | Web of Science | Medline38
Schuler D ,Horvath E ,Koos R , et al. Safety of dexrazoxane in children with ALL undergoing anthracycline therapy: preliminary results of a prospective pilot study. Pediatr Hematol Oncol 1997;14:93-94
CrossRef | Web of Science | Medline39
Hasinoff BB ,Hellmann K ,Herman EH ,Ferrans VJ . Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998;5:1-28
Web of Science | Medline40
Mladosievicova B ,Foltinova A ,Petrasova H ,Bernadic M ,Hulin I . Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane. Neoplasma 2001;48:61-65
Web of Science | Medline41
Herman EH ,Zhang J ,Rifai N , et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 2001;48:297-304
CrossRef | Web of Science | Medline42
Cox DR. The analysis of binary data. London: Methuen, 1970.
43
Agresti A. Categorical data analysis. New York: John Wiley, 1990.
44
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science45
Gianni L ,Zweiger JL ,Levy A ,Myers CE . Characterization of the cycle iron-mediated electron transfer from Adriamycin to molecular oxygen. J Biol Chem 1985;260:6820-6826
Web of Science | Medline46
Schroeder PE ,Hasinoff BB . The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. Cancer Chemother Pharmacol 2002;50:509-513
CrossRef | Web of Science | Medline47
Collinson PO ,Stubbs PJ . Are troponins confusing? Heart 2003;89:1285-1287
CrossRef | Web of Science | Medline48
Morrow DA ,Cannon CP ,Rifai N , et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001;286:2405-2412
CrossRef | Web of Science | Medline49
Lipshultz SE ,Sanders SP ,Goorin AM ,Krischer JP ,Sallan SE ,Colan SD . Monitoring for anthracycline cardiotoxicity. Pediatrics 1994;93:433-437
Web of Science | Medline50
Lipshultz SE ,Sanders SP ,Colan SD ,Goorin AM ,Sallan SE ,Krischer J . The anthracycline cardiotoxicity debate. Pediatrics 1994;94:781-782
Web of Science51
Hasinoff BB . Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc Toxicol 2002;2:111-118
CrossRef | Medline52
Simbre VC II ,Adams MJ ,Deshpande SS ,Duffy SA ,Miller TL ,Lipshultz SE . Cardiomyopathy caused by antineoplastic therapies. Curr Treat Options Cardiovasc Med 2001;3:493-505
CrossRef | Medline53
Tetef ML ,Synold TW ,Chow W , et al. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin Cancer Res 2001;7:1569-1576
Web of Science | Medline
- Citing Articles (106)
Citing Articles
1
Bjorn Redfors, Yangzhen Shao, Truls Råmunddal, Malin Lindbom, Margareta Scharin Täng, Pia Stillemark-Billton, Jan Boren, Elmir Omerovic. (2012) Effects of doxorubicin on myocardial expression of apolipoprotein-B. Scandinavian Cardiovascular Journal1-6
CrossRef2
Chieh-Hua Lee, Mei-Yi Hsieh, Ling-Wei Hsin, Hsiang-Chin Chen, Su-Chi Lo, Jia-Rong Fan, Wan-Ru Chen, Hung-Wei Chen, Nei-Li Chan, Tsai-Kun Li. (2012) Anthracenedione-methionine Conjugates are Novel Topoisomerase II-targeting Anticancer Agents with Favorable Drug Resistance Profiles. Biochemical Pharmacology
CrossRef3
Stanley Chaleff, Craig A. Hurwitz, Myron Chang, Gary Dahl, Todd A. Alonzo, Howard Weinstein. (2011) Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a Paediatric Oncology Group study. British Journal of Haematologyno-no
CrossRef4
S Romano, S Fratini, E Ricevuto, V Procaccini, G Stifano, M Mancini, M Di Mauro, C Ficorella, M Penco. (2011) Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. British Journal of Cancer
CrossRef5
Daniela Cardinale, Michela Salvatici, Maria T. Sandri. (2011) Review: Role of biomarkers in cardioncology. Clinical Chemistry and Laboratory Medicine---
CrossRef6
Joy M. Fulbright, Sripriya Raman, Wendy S. McClellan, Keith J. August. (2011) Late Effects of Childhood Leukemia Therapy. Current Hematologic Malignancy Reports 6:3, 195-205
CrossRef7
Bonnie Ky, Joseph R. Carver. (2011) Biomarker Approach to the Detection and Cardioprotective Strategies During Anthracycline Chemotherapy. Heart Failure Clinics 7:3, 323-331
CrossRef8
Ronald M. Witteles, Michael B. Fowler, Melinda L. Telli. (2011) Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?. Heart Failure Clinics 7:3, 333-344
CrossRef9
Elvira C van Dalen, Huib N Caron, Heather O Dickinson, Leontien CM Kremer, Elvira C van Dalen. 2011. Cardioprotective interventions for cancer patients receiving anthracyclines. .
CrossRef10
Daniela Cardinale. (2011) Treatment and prevention of cardiotoxicity due to anticancer therapy. Journal of Cardiovascular Echography 21:2, 92-100
CrossRef11
Lynda M. Vrooman, Donna S. Neuberg, Kristen E. Stevenson, Barbara L. Asselin, Uma H. Athale, Luis Clavell, Peter D. Cole, Kara M. Kelly, Eric C. Larsen, Caroline Laverdière, Bruno Michon, Marshall Schorin, Cindy L. Schwartz, Harvey J. Cohen, Steven E. Lipshultz, Lewis B. Silverman, Stephen E. Sallan. (2011) The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. European Journal of Cancer 47:9, 1373-1379
CrossRef12
Petra Temming, Amrana Qureshi, Juliane Hardt, Alison D. Leiper, Gillian Levitt, Phillip J. Ancliff, David K.H. Webb. (2011) Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: Retrospective cohort study in a single centre in the United Kingdom. Pediatric Blood & Cancer 56:4, 625-630
CrossRef13
Barry H. Trachtenberg, David C. Landy, Vivian I. Franco, Jacqueline M. Henkel, Elliot J. Pearson, Tracie L. Miller, Steven E. Lipshultz. (2011) Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer. Pediatric Cardiology 32:3, 342-353
CrossRef14
Steliana Ghibu, Stéphanie Delemasure, Carole Richard, Jean-Claude Guilland, Laurent Martin, Ségolène Gambert, Luc Rochette, Catherine Vergely. (2011) General oxidative stress during doxorubicin-induced cardiotoxicity in rats: Absence of cardioprotection and low antioxidant efficiency of alpha-lipoic acid. Biochimie
CrossRef15
Syed Wamique Yusuf, Nasreen A Ilias-Khan, Jean-Bernard Durand. (2011) Chemotherapy-induced cardiomyopathy. Expert Review of Cardiovascular Therapy 9:2, 231-243
CrossRef16
Lynne G. Maxwell, Salvatore R. Goodwin, Thomas J. Mancuso, Victor C. Baum, Aaron L. Zuckerberg, Philip G. Morgan, Etsuro K. Motoyama, Peter J. Davis, Kevin J. Sullivan. 2011. Systemic Disorders. , 1098-1182.
CrossRef17
Vivian I. Franco, Jacqueline M. Henkel, Tracie L. Miller, Steven E. Lipshultz. (2011) Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines. Cardiology Research and Practice 2011, 1-13
CrossRef18
T. Eschenhagen, T. Force, M. S. Ewer, G. W. de Keulenaer, T. M. Suter, S. D. Anker, M. Avkiran, E. de Azambuja, J.-L. Balligand, D. L. Brutsaert, G. Condorelli, A. Hansen, S. Heymans, J. A. Hill, E. Hirsch, D. Hilfiker-Kleiner, S. Janssens, S. de Jong, G. Neubauer, B. Pieske, P. Ponikowski, M. Pirmohamed, M. Rauchhaus, D. Sawyer, P. H. Sugden, J. Wojta, F. Zannad, A. M. Shah. (2011) Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure 13:1, 1-10
CrossRef19
W. M. FitzPatrick, N. G. Dervisis, B. E. Kitchell. (2010) Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient*. Veterinary and Comparative Oncology 8:4, 273-282
CrossRef20
Steven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, Stephen E Sallan, Lewis B Silverman, Tracie L Miller, Elly V Barry, Barbara L Asselin, Uma Athale, Luis A Clavell, Eric Larsen, Albert Moghrabi, Yvan Samson, Bruno Michon, Marshall A Schorin, Harvey J Cohen, Donna S Neuberg, E John Orav, Steven D Colan. (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. The Lancet Oncology 11:10, 950-961
CrossRef21
Paolo G. Rusconi, David A. Ludwig, Christopher Ratnasamy, Robert Mas, William G. Harmon, Steven D. Colan, Steven E. Lipshultz. (2010) Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure. American Heart Journal 160:4, 776-783
CrossRef22
Winston W. Huh, Norman Jaffe, Jean-Bernard Durand, Mark F. Munsell, Cynthia E. Herzog. (2010) COMPARISON OF DOXORUBICIN CARDIOTOXICITY IN PEDIATRIC SARCOMA PATIENTS WHEN GIVEN WITH DEXRAZOXANE VERSUS AS CONTINUOUS INFUSION. Pediatric Hematology-Oncology 27:7, 546-557
CrossRef23
Jean-Jacques Monsuez, Jean-Christophe Charniot, Noëlle Vignat, Jean-Yves Artigou. (2010) Cardiac side-effects of cancer chemotherapy. International Journal of Cardiology 144:1, 3-15
CrossRef24
Douglas B. Sawyer, Xuyang Peng, Billy Chen, Laura Pentassuglia, Chee Chew Lim. (2010) Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?. Progress in Cardiovascular Diseases 53:2, 105-113
CrossRef25
Jerónimo Sánchez-Medina, Oscar Gonzalez-Ramella, Sergio Gallegos-Castorena. (2010) The Effect of Dexrazoxane for Clinical and Subclinical Cardiotoxicity in Children With Acute Myeloid Leukemia. Journal of Pediatric Hematology/Oncology 32:4, 294-297
CrossRef26
Rebecca Scully, Steven E. Lipshultz. 2010. Cardiovascular Toxicity of Antitumor Drugs: Dimensions of the Problem in Children. , 97-126.
CrossRef27
Fabio Galetta, Ferdinando Franzoni, Giulia Cervetti, Francesco Regoli, Poupak Fallahi, Leonardo Tocchini, Angelo Carpi, Alessandro Antonelli, Mario Petrini, Gino Santoro. (2010) In vitro and in vivo study on the antioxidant activity of dexrazoxane. Biomedicine & Pharmacotherapy 64:4, 259-263
CrossRef28
Jennifer NA Silva, Charles E Canter. (2010) Current management of pediatric dilated cardiomyopathy. Current Opinion in Cardiology 25:2, 80-87
CrossRef29
L B Silverman, K E Stevenson, J E O'Brien, B L Asselin, R D Barr, L Clavell, P D Cole, K M Kelly, C Laverdiere, B Michon, M A Schorin, C L Schwartz, E W O'Holleran, D S Neuberg, H J Cohen, S E Sallan. (2010) Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia 24:2, 320-334
CrossRef30
Hyoung Soo Choi, Eun Sil Park, Hyoung Jin Kang, Hee Young Shin, Chung Il Noh, Yong Soo Yun, Hyo Seop Ahn, Jung Yun Choi. (2010) Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors. Journal of Korean Medical Science 25:9, 1336
CrossRef31
Steven E Lipshultz, James D Wilkinson, Sarah E Messiah, Tracie L Miller. (2009) Clinical research directions in pediatric cardiology. Current Opinion in Pediatrics 21:5, 585-593
CrossRef32
Andreas Goetzenich, Nima Hatam, Alma Zernecke, Christian Weber, Tanja Czarnotta, Rüdiger Autschbach, Stefan Christiansen. (2009) Alteration of Matrix Metalloproteinases in Selective Left Ventricular Adriamycin-Induced Cardiomyopathy in the Pig. The Journal of Heart and Lung Transplantation 28:10, 1087-1093
CrossRef33
Kuldeep Maradia, Maya Guglin. (2009) Pharmacologic Prevention of Anthracycline-Induced Cardiomyopathy. Cardiology in Review 17:5, 243-252
CrossRef34
Brian R. Berridge, Syril Pettit, Dana B. Walker, Alan S. Jaffe, Albert E. Schultze, Eugene Herman, William J. Reagan, Steven E. Lipshultz, Fred S. Apple, Malcolm J. York. (2009) A translational approach to detecting drug-induced cardiac injury with cardiac troponins: Consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. American Heart Journal 158:1, 21-29
CrossRef35
Marzia Lotrionte, Giovanni Palazzoni, Rosaria Natali, Gianluca Comerci, Antonio Abbate, Silvia Di Persio, Giuseppe G.L. Biondi-Zoccai. (2009) Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points. International Journal of Cardiology 135:1, 72-77
CrossRef36
ZhongGuang Luo, Lu Zhong, XiaoFeng Han, HaiRong Wang, JiHua Zhong, ZhengHua Xuan. (2009) Astragalus membranaceus prevents daunorubicin-induced apoptosis of cultured neonatal cardiomyocytes: role of free radical effect of Astragalus membranaceus on daunorubicin cardiotoxicity. Phytotherapy Research 23:6, 761-767
CrossRef37
Childhood Acute Lymphoblastic Leuka. (2009) Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. British Journal of Haematology 145:3, 376-388
CrossRef38
C.E. Pedreira, L. Macrini, M.G. Land, E.S. Costa. (2009) New Decision Support Tool for Treatment Intensity Choice in Childhood Acute Lymphoblastic Leukemia. IEEE Transactions on Information Technology in Biomedicine 13:3, 284-290
CrossRef39
Maria Virginia C.L. Appleyard, Mary A. O'Neill, Karen E. Murray, Fiona E.M. Paulin, Susan E. Bray, Neil M. Kernohan, David A. Levison, David P. Lane, Alastair M. Thompson. (2009) Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. International Journal of Cancer 124:2, 465-472
CrossRef40
Kevin R. Kozak, Theodore S. Hong, Patrick M. Sluss, Elizabeth L. Lewandrowski, Samir L. Aleryani, Shannon M. MacDonald, Noah C. Choi, Torunn I. Yock. (2008) Cardiac blood biomarkers in patients receiving thoracic (chemo)radiation. Lung Cancer 62:3, 351-355
CrossRef41
Benjamin W. Eidem. (2008) Identification of Anthracycline Cardiotoxicity: Left Ventricular Ejection Fraction Is Not Enough. Journal of the American Society of Echocardiography 21:12, 1290-1292
CrossRef42
Shufeng Li, Mingyan E, Bo Yu. (2008) Adriamycin induces myocardium apoptosis through activation of nuclear factor κB in rat. Molecular Biology Reports 35:4, 489-494
CrossRef43
Robin L Jones. (2008) Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Review of Cardiovascular Therapy 6:10, 1311-1317
CrossRef44
Ioannis Germanakis, Nikol Anagnostatou, Maria Kalmanti. (2008) Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatric Blood & Cancer 51:3, 327-333
CrossRef45
Steven E. Lipshultz, Valeriano C. Simbre, Sema Hart, Nader Rifai, Stuart R. Lipsitz, Linda Reubens, Robert A. Sinkin. (2008) Frequency of Elevations in Markers of Cardiomyocyte Damage in Otherwise Healthy Newborns. The American Journal of Cardiology 102:6, 761-766
CrossRef46
Brent Anderson, Douglas B Sawyer. (2008) Predicting and preventing the cardiotoxicity of cancer therapy. Expert Review of Cardiovascular Therapy 6:7, 1023-1033
CrossRef47
Fotiní Dodos, Teresa Halbsguth, Erland Erdmann, Uta C. Hoppe. (2008) Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clinical Research in Cardiology 97:5, 318-326
CrossRef48
Elvira C van Dalen, Huib N Caron, Heather O Dickinson, Leontien CM Kremer, Elvira C van Dalen. 2008. Cardioprotective interventions for cancer patients receiving anthracyclines. .
CrossRef49
Morie A. Gertz. (2008) Troponin in hematologic oncology. Leukemia & Lymphoma 49:2, 194-203
CrossRef50
Miho Maeda. (2008) Late Effects of Childhood Cancer: Life-threatening Issues. Journal of Nippon Medical School 75:6, 320-324
CrossRef51
Sanjeev Aggarwal, Michael D. Pettersen, Kanta Bhambhani, Joellyn Gurczynski, Ronald Thomas, Thomas L'Ecuyer. (2007) B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatric Blood & Cancer 49:6, 812-816
CrossRef52
John G. Gribben. 2007. Management of Haematological Malignancies. .
CrossRef53
C. J. McMahon, H. Murchan, T. Prendiville, M. Burch. (2007) Parvovirus B19 Infection Associated with Dilated Cardiomyopathy in Patients with Previous Anthracycline Exposure. Pediatric Cardiology 28:5, 394-395
CrossRef54
J. Bryant, J. Picot, L. Baxter, G. Levitt, I. Sullivan, A. Clegg. (2007) Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: A systematic review. European Journal of Cancer 43:13, 1959-1966
CrossRef55
Sivan Ekstein, Amiram Nir, Azaria JJT Rein, Zeev Perles, Benjamin Bar-Oz, Lea Salpeter, Nurit Algur, Michael Weintraub. (2007) N-Terminal-proB-Type Natriuretic Peptide as a Marker for Acute Anthracycline Cardiotoxicity in Children. Journal of Pediatric Hematology/Oncology 29:7, 440-444
CrossRef56
Christie E. Delaney, Sean P. Hopkins, Christina L. Addison. (2007) Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells. Cancer Letters 252:2, 195-207
CrossRef57
Rebecca E. Scully, Steven E. Lipshultz. (2007) Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovascular Toxicology 7:2, 122-128
CrossRef58
Billy Chen, Xuyang Peng, Laura Pentassuglia, Chee Chew Lim, Douglas B. Sawyer. (2007) Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovascular Toxicology 7:2, 114-121
CrossRef59
C Uderzo, M Pillon, P Corti, G Tridello, F Tana, F Zintl, K Nysom, C Galambrun, F Fagioli, S Varotto, C Messina, A Verdeguer, C Urban, M Faraci, G Dini, S Fedeli, A Tichelli, A Rovelli, G Socié. (2007) Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties. Bone Marrow Transplantation 39:11, 667-675
CrossRef60
Steven E Lipshultz. (2007) Heart failure in childhood cancer survivors. Nature Clinical Practice Oncology 4:6, 334-335
CrossRef61
Gurusher S. Panjrath, Virender Patel, Carolina I. Valdiviezo, Navneet Narula, Jagat Narula, Diwakar Jain. (2007) Potentiation of Doxorubicin Cardiotoxicity by Iron Loading in a Rodent Model. Journal of the American College of Cardiology 49:25, 2457-2464
CrossRef62
Elly Barry, Jorge A Alvarez, Rebecca E Scully, Tracie L Miller, Steven E Lipshultz. (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opinion on Pharmacotherapy 8:8, 1039-1058
CrossRef63
Laura-Maria S. Madanat, Päivi M. Lähteenmäki, Jouni Alin, Toivo T. Salmi. (2007) The natural history of thyroid function abnormalities after treatment for childhood cancer. European Journal of Cancer 43:7, 1161-1170
CrossRef64
Gary E. Stapleton, Stacie L. Stapleton, Ana Martinez, Nancy A. Ayres, John P. Kovalchin, Louis I. Bezold, Ricardo Pignatelli, Benjamin W. Eidem. (2007) Evaluation of Longitudinal Ventricular Function with Tissue Doppler Echocardiography in Children Treated with Anthracyclines. Journal of the American Society of Echocardiography 20:5, 492-497
CrossRef65
Elvira C. van Dalen, Huib N. Caron, Leontien C.M. Kremer. (2007) Prevention of anthracycline-induced cardiotoxicity in children: The evidence. European Journal of Cancer 43:7, 1134-1140
CrossRef66
Marcelo G. Paiva. (2007) Measuring the impact of dexrazoxane cardioprotection-response. Pediatric Blood & Cancer 48:4, 485-485
CrossRef67
David R. Freyer. (2007) Measuring the impact of dexrazoxane cardioprotection. Pediatric Blood & Cancer 48:4, 483-484
CrossRef68
U.C. Hoppe. (2007) Herzerkrankungen bei Tumoren und Tumortherapie. Der Internist 48:3, 268-275
CrossRef69
Jorge A Alvarez, Rebecca E Scully, Tracie L Miller, F Daniel Armstrong, Louis S Constine, Debra L Friedman, Steven E Lipshultz. (2007) Long-term effects of treatments for childhood cancers. Current Opinion in Pediatrics 19:1, 23-31
CrossRef70
Cecilia Nistic??, Emilio Bria, Federica Cuppone, Armando Carpino, Gianluigi Ferretti, Gaetano Vitelli, Isabella Sperduti, Francesca Calabretta, Giuseppe Toglia, Silverio Tomao, Francesco Cognetti, Edmondo Terzoli. (2007) Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin???paclitaxel in metastatic breast cancer patients. Anti-Cancer Drugs 18:2, 227-232
CrossRef71
J Bryant, J Picot, L Baxter, G Levitt, I Sullivan, A Clegg. (2007) Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. British Journal of Cancer 96:2, 226-230
CrossRef72
Ei Ikegami, Ryuji Fukazawa, Masaru Kanbe, Miki Watanabe, Masanori Abe, Makoto Watanabe, Mitsuhiro Kamisago, Miharu Hajikano, Yasuhiro Katsube, Shunichi Ogawa. (2007) Edaravone, a Potent Free Radical Scavenger, Prevents Anthracycline-Induced Myocardial Cell Death. Circulation Journal 71:11, 1815-1820
CrossRef73
Joris W.F. Uges, Albert M. Vollaard, Erik B. Wilms, Rolf E. Brouwer. (2006) Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane. International Journal of Clinical Oncology 11:6, 467-470
CrossRef74
Peter H. Wiernik. (2006) Plasma cell dyscrasias and leukemias. Update on Cancer Therapeutics 1:4, 539-567
CrossRef75
Robin L Jones, Charles Swanton, Michael S Ewer. (2006) Anthracycline cardiotoxicity. Expert Opinion on Drug Safety 5:6, 791-809
CrossRef76
Alexander J Chou, Richard Gorlick. (2006) Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Review of Anticancer Therapy 6:7, 1075-1085
CrossRef77
Gerald Batist, Lyndsay Harris, Nozar Azarnia, Lily Waiyee Lee, Pascual Daza-Ramirez. (2006) Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anti-Cancer Drugs 17:5, 587-595
CrossRef78
Élie Azoulay, Benoît Schlemmer. (2006) Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Medicine 32:6, 808-822
CrossRef79
Steven E. Lipshultz. (2006) Exposure to Anthracyclines During Childhood Causes Cardiac Injury. Seminars in Oncology 33, 8-14
CrossRef80
M. Paulides, A. Kremers, W. Stöhr, S. Bielack, H. Jürgens, J. Treuner, J.D. Beck, T. Langer, . (2006) Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: A report of the late effects surveillance system (LESS). Pediatric Blood & Cancer 46:4, 489-495
CrossRef81
W. Pönisch, D. Niederwieser. (2006) Folgeerkrankungen nach Chemotherapie. Der Internist 47:3, 266-274
CrossRef82
Smita Bhatia, Anna T. Meadows. (2006) Long-term follow-up of childhood cancer survivors: Future directions for clinical care and research. Pediatric Blood & Cancer 46:2, 143-148
CrossRef83
Pui, Ching-Hon, Evans, William E., . (2006) Treatment of Acute Lymphoblastic Leukemia. New England Journal of Medicine 354:2, 166-178
Full Text84
David L. Reich, Alexander Mittnacht, Joel A. Kaplan. 2006. Uncommon Cardiac Diseases. , 29-76.
CrossRef85
Steven E. Lipshultz, Harvey Cohen, Steven D. Colan, Eugene H. Herman. (2006) The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity. Leukemia & Lymphoma 47:8, 1454-1458
CrossRef86
Evanthia Bernitsas, Wei Wei, Daniel D. Mikol. (2006) Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Annals of Neurology 59:1, 206-209
CrossRef87
Lars Sl??rdal, Olav Spigset. (2006) Heart Failure Induced by Non-Cardiac Drugs. Drug Safety 29:7, 567-586
CrossRef88
J STOCKMANIII. (2006) The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children With Acute Lymphoblastic LeukemiaLipshultz SE, Rifai N, Dalton VM, et al (Univ of Miami, Fla; Univ of Rochester, NY; Children's Hosp, Boston; et al) N Engl Med 351:145–153, 2004§. Yearbook of Pediatrics 2006, 448-449
CrossRef89
Marcelo G. Paiva, Antônio S. Petrilli, Valdir A. Moisés, Carla Renata Donato Macedo, Cristiana Tanaka, Orlando Campos. (2005) Cardioprotective effect of dexrazoxane during treatment with doxorubicin: A study using low-dose dobutamine stress echocardiography. Pediatric Blood & Cancer 45:7, 902-908
CrossRef90
Stephen E. Sallan, Steven E. Lipshultz. (2005) Wise up: Do not do it without protection!. Pediatric Blood & Cancer 45:7, 872-873
CrossRef91
Karlijn A. Wouters, Leontien C. M. Kremer, Tracie L. Miller, Eugene H. Herman, Steven E. Lipshultz. (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. British Journal of Haematology 131:5, 561-578
CrossRef92
Lubomir Elbl, Hana Hrstkova, Iva Tomaskova, Bohumir Blazek, Jaroslav Michalek. (2005) Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients. European Journal of Pediatrics 164:11, 678-684
CrossRef93
M Aricó, A Baruchel, Y Bertrand, A Biondi, V Conter, T Eden, H Gadner, P Gaynon, K Horibe, S P Hunger, G Janka-Schaub, G Masera, J Nachman, R Pieters, M Schrappe, K Schmiegelow, M G Valsecchi, C-H Pui. (2005) The Seventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Palermo, Italy, January 29–30, 2005. Leukemia 19:7, 1145-1152
CrossRef94
Barry Anderson. (2005) Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Pediatric Blood & Cancer 44:7, 584-588
CrossRef95
Michaela Adamcová, Martin Šterba, Tomáš Šimunek, Anna Potácová, Olga Popelová, Yvona Mazurová, Vladimír Geršl. (2005) Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opinion on Drug Safety 4:3, 457-472
CrossRef96
Yukitaka Shizukuda, Satoaki Matoba, Omar Y. Mian, Tammy Nguyen, Paul M. Hwang. (2005) Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Molecular and Cellular Biochemistry 273:1-2, 25-32
CrossRef97
Jean-Hugues Dalle, Albert Moghrabi, Pierre Rousseau, Jean-Marie Leclerc, Stephane Barrette, Mark L Bernstein, Josette Champagne, Michele David, Jocelyn Demers, Michel Duval, Heather Hume, Patrick Meyer, Martin A Champagne. (2005) Second Induction in Pediatric Patients With Recurrent Acute Lymphoid Leukemia Using DFCI-ALL Protocols. Journal of Pediatric Hematology/Oncology 27:2, 73-79
CrossRef98
Valeriano C Simbre, Sarah A Duffy, Gul H Dadlani, Tracie L Miller, Steven E Lipshultz. (2005) Cardiotoxicity of Cancer Chemotherapy. Pediatric Drugs 7:3, 187-202
CrossRef99
Hideto To, Tsuyoshi Saito, Ohdo Shigehiro, Shun Higuchi, Akio Fujimura, Eiji Kobayashi. (2005) Doxorubicin Chronotherapy in??Japanese Outpatients with??Breast Cancer. Drugs in R & D 6:2, 101-107
CrossRef100
Diana Iarussi, Paolo Indolfi, Fiorina Casale, Vincenzo Martino, Maria Teresa Di Tullio, Raffaele Calabr??. (2005) Anthracycline-Induced Cardiotoxicity in Children with Cancer. Pediatric Drugs 7:2, 67-76
CrossRef101
Risto S Cvetkovi??, Lesley J Scott. (2005) Dexrazoxane. Drugs 65:7, 1005-1024
CrossRef102
Mike M Hawkins. (2004) Long-term survivors of childhood cancers: what knowledge have we gained?. Nature Clinical Practice Oncology 1:1, 26-31
CrossRef103
Jeffrey H Silber. (2004) Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?. Nature Clinical Practice Oncology 1:1, 16-17
CrossRef104
(2004) Doxorubicin-Induced Myocardial Injury. New England Journal of Medicine 351:18, 1908-1909
Full Text105
Dennis Raisch, Mark Holdsworth, Patricia Marshik, Heather Campbell. (2004) Pharmacoeconomic analysis of therapies for pediatric patients. Expert Review of Pharmacoeconomics & Outcomes Research 4:5, 483-487
CrossRef106
Kremer, Leontine C.M., Caron, Huib N., . (2004) Anthracycline Cardiotoxicity in Children. New England Journal of Medicine 351:2, 120-121
Full Text
- Letters
